Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis

Wardhani, Shinta Oktya; Fajar, Jonny Karunia; Wulandari, Laksmi; Soegiarto, Gatot; Purnamasari, Yeni; Asmiragani, Anisa; Maliga, Helnida Anggun; Ilmawan, Muhammad; Seran, Gloriana; Iskandar, Dheka Sapti; Ndapa, Conchita Emiliana; Hamat, Viviana; Wahyuni, Rafika Ajeng; Cyntia, Linda Oktaviana Suci; Maarang, Feronika Maryanti; Beo, Yosef Andrian; Adar, Olivera Agnes; Rakhmadhan, Iraky Mardya; Shantikaratri, Emilia Tiara; Putri, Ayu Sekarani Damana; Wahdini, Rizqa; Broto, Endang Pati; Suwanto, Agnes Wanda; Tamara, Fredo; Mahendra, Aditya Indra; Winoto, Eden Suryoiman; Krisna, Pratista Adi; Harapan, Harapan

doi:10.12688/f1000research.36396.3

Cited by 8 publications

(5 citation statements)

References 50 publications

(54 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The other two meta-analysis showed a reduction in mortality but disappeared in RCTs, strengthening our results (41,42). Contrary to our study, several previous metaanalyses (43)(44)(45)(46) showed that CP could help reduce mortality in COVID-19 patients, and their level of evidence was lower than the present study because most of them included not only RCTs but also observation studies in their analysis. Therefore, our study provided more solid evidence.…”

Section: Discussionsupporting

confidence: 68%

The Effectiveness of Convalescent Plasma for the Treatment of Novel Corona Virus Disease 2019: A Systematic Review and Meta-Analysis

Cao

Chen

et al. 2021

Front. Med.

View full text Add to dashboard Cite

Background: Coronavirus disease 2019 (COVID-19), sweeping across the world, has created a worldwide pandemic. Effective treatments of COVID-19 are extremely urgent.Objective: To analyze the efficacy and safety of convalescent plasma (CCP) on patients with COVID-19.Methods: All the relevant studies were searched from PubMed, EMBASE,Cochrane library, Scopus, Web of Science, CBM, CNKI, Wan fang, VIP, Medrxiv, Biorxiv, and SSRN on July 19, 2021. PICOS criteria were as follows: (P) the study interests were human subjects with the infection of COVID-19; (I) the intervention of interest was CCP; (C) comparator treatments contained placebo, sham therapy, and standard treatment; (O) the primary outcome was mortality rates by the novel coronavirus. The secondary outcomes included the incidence of serious adverse events, the rate of ICU admission and mechanical ventilation (MV); the length of hospital stay; the duration of MV and ICU stay; the antibody levels, inflammatory factor levels, and viral loads. (S) Only randomized controlled trials (RCTs) of CCP were included. Subanalysis, quality assessment, sensitive analysis, and publication bias were conducted by two reviewers independently.Results: Sixteen RCTs were included and enrolled a total of 16,296 participants in this meta-analysis. The pooled data showed that no significant difference was observed in reducing the rate of overall mortality between CCP treatment group and placebo group (OR 0.96; 95% CI 0.90 to 1.03; p = 0.30; I2 = 6%). According to the results of subgroup analysis, severe or critical patients with CCP showed significant difference in reducing the 28-day mortality of compared with placebo (OR 0.58, 95% CI 0.36 to 0.93, p = 0.02, I2 = 0%). CCP groups have a significantly shorter duration of MV compared with the control group (weighted MD −1.00, 95% CI −1.86 to −0.14 d p = 0.02, I2 = 0%). No significant difference was observed in the length of hospital stay, the duration of ICU, and the rate of ICU and MV. There is no conclusive evidence about the safety of CCP.Conclusion: Convalescent plasma can significantly reduce the 28-day mortality of severe or critical COVID-19 patients and the duration of MV. However, more evidence was needed to prove the safety of convalescent plasma.

show abstract

Section: Discussionsupporting

confidence: 68%

The Effectiveness of Convalescent Plasma for the Treatment of Novel Corona Virus Disease 2019: A Systematic Review and Meta-Analysis

Cao

Chen

et al. 2021

Front. Med.

View full text Add to dashboard Cite

show abstract

“…Although, most controlled trials have shown negative results, some studies and case reports of convalescent plasma therapy for COVID-19 have reported some effectiveness in COVID-19 patients with severe disease [125]. A recent meta-analysis showed that convalescent plasma as an adjunctive therapy could reduce the mortality rate among COVID-19 patients [126].…”

Section: Convalescent Plasmamentioning

confidence: 99%

The Immunology of SARS-CoV-2 Infection and Vaccines in Solid Organ Transplant Recipients

Dęborska−Materkowska

Kamińska

2021

Viruses

View full text Add to dashboard Cite

Since its outbreak in December 2019, the coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), led to an enormous rise in scientific response with an excess of COVID-19-related studies on the pathogenesis and potential therapeutic approaches. Solid organ transplant (SOT) recipients are a heterogeneous population with long-lasting immunosuppression as a joining element. Immunocompromised patients are a vulnerable population with a high risk of severe infections and an increased infection-related mortality rate. It was postulated that the hyperinflammatory state due to cytokine release syndrome during severe COVID-19 could be alleviated by immunosuppressive therapy in SOT patients. On the other hand, it was previously established that T cell-mediated immunity, which is significantly weakened in SOT recipients, is the main component of antiviral immune responses. In this paper, we present the current state of science on COVID-19 immunology in relation to solid organ transplantation with prospective therapeutic and vaccination strategies in this population.

show abstract

“…In summary, the early application of CP therapy in patients with severe COVID-19 can rapidly improve the condition of the patient, and the therapy is generally effective and safe. This therapy can reduce the risk of COVID-19 progressing from severe to critical, lower the mortality rate, [ 24 ] and help raise the rescue success rate in patients with severe disease. In the absence of effective anti-SARS-CoV-2 drugs, CP therapy is an alternative method for treating patients with severe COVID-19 using adjuvant therapy.…”

Section: Discussionmentioning

confidence: 99%

“…In the absence of effective anti-SARS-CoV-2 drugs, CP therapy is an alternative method for treating patients with severe COVID-19 using adjuvant therapy. [ 24 ]…”

Section: Discussionmentioning

confidence: 99%

Convalescent plasma therapy for patients with severe COVID-19: A case series study

et al. 2022

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is a novel acute respiratory infectious disease that can lead to multiple-organ dysfunction in patients with severe disease. However, there is a lack of effective antiviral drugs for COVID-19. Herein, we investigated the efficacy and safety of convalescent plasma (CP) therapy for treating severe COVID-19 in an attempt to explore new therapeutic methods.The clinical data of 3 imported patients with severe COVID-19 who underwent treatment with CP and who were quarantined and treated in a designated COVID-19 hospital from March 2020 to April 2020 were collected and analyzed.The 3 patients, including a 57-year-old male, 65-year-old female, and 59-year-old female, were clinically classified as having severe COVID-19. The main underlying diseases included hypertension, diabetes, sequelae of cerebral infarction, and postoperative thyroid adenoma. The common symptoms included cough, fever, and shortness of breath. All patients received antiviral drugs and other supportive treatments. Additionally, CP treatment was administered. At 48 to 72 hours after the CP transfusion, all 3 of the patients exhibited an improvement and alleviation of symptoms, an elevated arterial oxygen saturation, and decreased C-reactive protein and interleukin-6 levels. The counts of the total lymphocytes and T lymphocytes (CD3+) and their subsets (CD4 + and CD8+) were also obviously increased. Repeated chest computed tomography also revealed obvious absorption of the lesions in the bilateral lungs. Only 1 patient had a mild allergic reaction during the CP infusion, but no severe adverse reactions were observed.The early treatment with CP in patients with severe COVID-19 can rapidly improve the condition of the patients, and CP therapy is generally effective and safe.Abbreviations: SaO 2 = arterial oxygen saturation, CT = computed tomography, CP = convalescent plasma, COVID-19 = coronavirus disease 2019, CRP = C-reactive protein, IL-6 =interleukin-6, SARS-CoV-2 = severe acute respiratory syndromeassociated coronavirus-2.

show abstract

Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis

Cited by 8 publications

References 50 publications

The Effectiveness of Convalescent Plasma for the Treatment of Novel Corona Virus Disease 2019: A Systematic Review and Meta-Analysis

The Effectiveness of Convalescent Plasma for the Treatment of Novel Corona Virus Disease 2019: A Systematic Review and Meta-Analysis

The Immunology of SARS-CoV-2 Infection and Vaccines in Solid Organ Transplant Recipients

Convalescent plasma therapy for patients with severe COVID-19: A case series study

Contact Info

Product

Resources

About